Evolving Considerations for Therapeutic Drug Monitoring in IBD: Who, What, Why, When, and How?

Tuesday, December 6, 2022

4:20 PM – 5:20 PM

Location: Northern Hemisphere D

Chair(s)

Bruce E. Sands, MD, MS, FACG

Chief, Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Speaker(s)

Maria T. Abreu, MD

Director, Crohn's & Colitis Center, Professor of Medicine, Professor of Microbiology and Immunology; 2019 Sherman Prize Recipient
University of Miami Miller School of Medicine
Miami, Florida
Adam S. Cheifetz, MD

Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Disclosure(s):

Bruce E. Sands, MD, MS, FACG: disclosed no relevant financial relationship with any ineligible company (commercial interest).

This session is supported by an independent educational grant from Prometheus Laboratories Inc.

4:20 PM Introduction and Pre-Activity Survey
Bruce E. Sands, MD, MS, FACG

4:25 PM TDM: Definitions and Questions
Bruce E. Sands, MD, MS, FACG

4:30 PM Reactive TDM (anti-TNFs)
Maria T. Abreu, MD

4:45 PM Proactive TDM (anti-TNFs)
Adam S. Cheifetz, MD

5:00 PM TDM for Non-Anti-TNF Biologics?
Bruce E. Sands, MD, MS, FACG

5:10 PM Panel Discussion Q&A and Post-Activity Survey
Bruce E. Sands, MD, MS, FACG; Maria T. Abreu, MD; Adam S. Cheifetz, MD

Learning Objectives:

Assess the utility of TDM in evaluating serum biologic drug concentrations in patients struggling with PNR and secondary LOR to anti-TNF therapy
Explain the differences between reactive and proactive TDM, including considerations for when to initiate each
Evaluate currently available assays for precision-guided dosing and TDM in the management of IBD